Literature DB >> 35381868

Magnetic resonance imaging (MRI) helps differentiate renal cell carcinoma with sarcomatoid differentiation from renal cell carcinoma without sarcomatoid differentiation.

Mitsuru Takeuchi1, Adam T Froemming2, Akira Kawashima3, Prabin Thapa2, Rickey E Carter2, John C Cheville2, R Houston Thompson2, Naoki Takahashi4.   

Abstract

PURPOSE: The aim of the present study is to identify predictive imaging findings and construct a diagnostic model for differentiating renal cell carcinoma (RCC) with and without sarcomatoid dedifferentiation (sRCC and non-sRCC).
METHODS: This study is a single-center retrospective study. All patients had magnetic resonance imaging (MRI) with gradient-echo T1-weighted images, single-shot T2-weighted images (T2WI), and enhanced nephrographic phase images. Forty pathologically confirmed sRCCs and 80 non-sRCCs were included in this study. Control cases were selected by matching the tumor diameter and the year of MRI. Two radiologists independently evaluated the following findings: growth pattern, presence of low-intensity area on T2WI in the tumor (T2LIA), presence of non-enhancing area, local tumor stage, and presence of regional lymphadenopathy. Two radiologists measured the diameter of the tumor, T2LIA, and the non-enhancing area. Multivariable logistic regression analysis was used to identify independent predictive factors for differentiating sRCC from non-sRCC. Selected variables were entered in the logistic regression model, and the area under the curve (AUC) was calculated for each reader with 95% confidence intervals (CIs).
RESULTS: Larger T2LIA-to-tumor diameter ratio, regional lymphadenopathy, and local tumor stage 4 were associated with sRCC, and selected for the subsequent construction of a logistic regression model. With this model, the AUCs were 0.76 (95% CI, 0.66-0.85) and 0.70 (95% CI, 0.59-0.81) for prediction of sRCC.
CONCLUSION: In conclusion, larger T2LIA-to-tumor diameter ratio, regional lymphadenopathy, and local tumor stage 4 are predictive findings of sRCC. As a result, the model constructed using these findings demonstrated a moderate degree of diagnostic accuracy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Diagnostic accuracy; MRI; Renal cell carcinoma; Sarcomatoid renal cell carcinoma

Mesh:

Year:  2022        PMID: 35381868     DOI: 10.1007/s00261-022-03501-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  17 in total

1.  MRI findings of sarcomatoid renal cell carcinoma in nine cases.

Authors:  Andrew B Rosenkrantz; Hersh Chandarana; Jonathan Melamed
Journal:  Clin Imaging       Date:  2011 Nov-Dec       Impact factor: 1.605

Review 2.  Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors:  Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

3.  Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?

Authors:  Brian Shuch; Jonathan Said; Jeff C La Rochelle; Ying Zhou; Gang Li; Tobias Klatte; Fairooz F Kabbinaavar; Allan J Pantuck; Arie S Belldegrun
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

4.  Characteristic MRI findings of sarcomatoid renal cell carcinoma dedifferentiated from clear cell renal carcinoma: radiological-pathological correlation.

Authors:  Mitsuru Takeuchi; Misugi Urano; Masaki Hara; Yukio Fujiyoshi; Hiroshi Inagaki; Yuta Shibamoto
Journal:  Clin Imaging       Date:  2013-07-06       Impact factor: 1.605

5.  Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT.

Authors:  Jonathan R Young; Jocelyn A Young; Daniel J A Margolis; Steven Sauk; James Sayre; Allan J Pantuck; Steven S Raman
Journal:  Acad Radiol       Date:  2017-05-18       Impact factor: 3.173

6.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Authors:  Brian I Rini; Thomas Powles; Michael B Atkins; Bernard Escudier; David F McDermott; Cristina Suarez; Sergio Bracarda; Walter M Stadler; Frede Donskov; Jae Lyun Lee; Robert Hawkins; Alain Ravaud; Boris Alekseev; Michael Staehler; Motohide Uemura; Ugo De Giorgi; Begoña Mellado; Camillo Porta; Bohuslav Melichar; Howard Gurney; Jens Bedke; Toni K Choueiri; Francis Parnis; Tarik Khaznadar; Alpa Thobhani; Shi Li; Elisabeth Piault-Louis; Gretchen Frantz; Mahrukh Huseni; Christina Schiff; Marjorie C Green; Robert J Motzer
Journal:  Lancet       Date:  2019-05-09       Impact factor: 79.321

Review 7.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.

Authors:  Brian Shuch; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Oncologist       Date:  2012-01-10

8.  Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.

Authors:  Paul L Crispen; Rodney H Breau; Cristine Allmer; Christine M Lohse; John C Cheville; Bradley C Leibovich; Michael L Blute
Journal:  Eur Urol       Date:  2010-09-15       Impact factor: 20.096

9.  MRI for differentiation of renal cell carcinoma with sarcomatoid component from other renal tumor types.

Authors:  Mitsuru Takeuchi; Tatsuya Kawai; Tomohiro Suzuki; Taku Naiki; Noriyasu Kawai; Yukio Fujiyoshi; Hiroshi Inagaki; Kenjiro Kohri; Masaki Hara; Yuta Shibamoto
Journal:  Abdom Imaging       Date:  2015-01

10.  A CT-Based Radiomics Approach for the Differential Diagnosis of Sarcomatoid and Clear Cell Renal Cell Carcinoma.

Authors:  Xiaoli Meng; Jun Shu; Yuwei Xia; Ruwu Yang
Journal:  Biomed Res Int       Date:  2020-07-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.